Insulin degludec : The new standard long acting insulin analogue for people with type 1 diabetes?

Dear Editor ; Two recent studies by Yamamoto et al. and Urakami et al. provide interesting results on the use of new long-acting insulin analogue, insulin degludec (IDeg) and gave us the opportunity to compare and discuss the data reported with those of our working group in Spain. IDeg was approved in Spain in January 2016, however during 2015 could be used in hospitals by requesting it as compassionate use in people with Type 1 diabetes mellitus with multiple hypoglycemic events. Between January and June 2015 we transfer to IDeg from insulin glargine (IGlar) as basal-bolus therapy in 50 patients with type 1 diabetes mellitus (mean age 39.8+-14.9 years ; 21 men / 29 women ; BMI 23.3+-2.5 kg/m2 ; IGlar once daily 38 patients, twice daily 12). At six months after starting IDeg, both fasting plasma glucose and HbA1c levels decreased significantly from 179.6+-55.5 mg/dL and 8.28+-1.1% at baseline to 152.9+-28.7 mg/dL and 7.88+-0.8% (p